| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 24 | 2025 | 271 | 5.890 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 22 | 2026 | 849 | 3.580 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2026 | 583 | 2.770 |
Why?
|
| Neoplasms, Second Primary | 6 | 2025 | 144 | 2.360 |
Why?
|
| Neoplasms | 20 | 2025 | 2968 | 2.200 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 249 | 1.880 |
Why?
|
| Telomere | 4 | 2016 | 221 | 1.380 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2026 | 142 | 1.280 |
Why?
|
| Down Syndrome | 2 | 2025 | 237 | 1.280 |
Why?
|
| Child | 64 | 2026 | 26383 | 1.240 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 313 | 1.160 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 312 | 1.130 |
Why?
|
| Telomere Shortening | 2 | 2021 | 34 | 1.090 |
Why?
|
| Telomerase | 3 | 2020 | 158 | 1.060 |
Why?
|
| Survivorship | 3 | 2024 | 46 | 1.030 |
Why?
|
| Adolescent | 45 | 2026 | 21021 | 0.960 |
Why?
|
| Mycoses | 2 | 2021 | 113 | 0.950 |
Why?
|
| Health Equity | 2 | 2024 | 78 | 0.890 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2026 | 1351 | 0.890 |
Why?
|
| Neutropenia | 5 | 2023 | 206 | 0.880 |
Why?
|
| Health Status Disparities | 2 | 2026 | 279 | 0.840 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 45 | 0.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 1270 | 0.810 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2026 | 3439 | 0.800 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 65 | 0.800 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 23 | 0.780 |
Why?
|
| Antineoplastic Agents | 5 | 2026 | 1811 | 0.760 |
Why?
|
| Humans | 80 | 2026 | 132194 | 0.720 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 48 | 0.720 |
Why?
|
| Radiotherapy | 3 | 2021 | 120 | 0.720 |
Why?
|
| Patient Preference | 1 | 2023 | 147 | 0.710 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 103 | 0.700 |
Why?
|
| Frailty | 2 | 2021 | 139 | 0.690 |
Why?
|
| Young Adult | 22 | 2026 | 10131 | 0.680 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 41 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2026 | 2873 | 0.650 |
Why?
|
| Methotrexate | 5 | 2025 | 344 | 0.640 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 189 | 0.630 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 204 | 0.630 |
Why?
|
| Antifungal Agents | 3 | 2024 | 298 | 0.610 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 268 | 0.600 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 116 | 0.590 |
Why?
|
| Internet | 2 | 2022 | 421 | 0.590 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 133 | 0.580 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.580 |
Why?
|
| Child, Preschool | 26 | 2026 | 15103 | 0.570 |
Why?
|
| Female | 48 | 2026 | 71459 | 0.560 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 125 | 0.550 |
Why?
|
| Prognosis | 12 | 2026 | 4965 | 0.550 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 81 | 0.550 |
Why?
|
| Male | 44 | 2026 | 65494 | 0.550 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 14 | 0.540 |
Why?
|
| Caregivers | 1 | 2023 | 586 | 0.540 |
Why?
|
| Biomarkers, Tumor | 3 | 2026 | 1624 | 0.540 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 166 | 0.530 |
Why?
|
| Siblings | 3 | 2019 | 204 | 0.520 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 58 | 0.520 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 323 | 0.500 |
Why?
|
| Infertility | 1 | 2017 | 79 | 0.500 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 80 | 0.490 |
Why?
|
| Genetic Variation | 2 | 2020 | 1577 | 0.490 |
Why?
|
| Cognition Disorders | 1 | 2020 | 565 | 0.480 |
Why?
|
| Risk Factors | 18 | 2026 | 11041 | 0.470 |
Why?
|
| Survivors | 5 | 2024 | 352 | 0.460 |
Why?
|
| Neutrophils | 1 | 2016 | 371 | 0.420 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 45 | 0.390 |
Why?
|
| Adult | 20 | 2026 | 31771 | 0.390 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 62 | 0.380 |
Why?
|
| Retrospective Studies | 19 | 2026 | 17772 | 0.380 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 1412 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 2 | 2025 | 111 | 0.370 |
Why?
|
| Steroids | 1 | 2013 | 172 | 0.370 |
Why?
|
| Induction Chemotherapy | 2 | 2025 | 55 | 0.360 |
Why?
|
| Infant | 18 | 2026 | 13356 | 0.360 |
Why?
|
| Obesity | 3 | 2018 | 2395 | 0.340 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 33 | 0.330 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 255 | 0.330 |
Why?
|
| Case-Control Studies | 5 | 2026 | 3461 | 0.330 |
Why?
|
| Hematology | 1 | 2011 | 41 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2025 | 5284 | 0.320 |
Why?
|
| Incidence | 5 | 2024 | 3358 | 0.320 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 896 | 0.320 |
Why?
|
| Cardiomyopathies | 2 | 2025 | 518 | 0.320 |
Why?
|
| Microcephaly | 1 | 2013 | 351 | 0.320 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 388 | 0.300 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.300 |
Why?
|
| Sterol Esterase | 1 | 2009 | 19 | 0.300 |
Why?
|
| Isoantibodies | 1 | 2009 | 62 | 0.300 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 82 | 0.290 |
Why?
|
| Cellular Senescence | 1 | 2010 | 216 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2102 | 0.280 |
Why?
|
| Anthracyclines | 3 | 2025 | 43 | 0.270 |
Why?
|
| Texas | 5 | 2026 | 3657 | 0.270 |
Why?
|
| HLA Antigens | 1 | 2009 | 226 | 0.270 |
Why?
|
| Acute Kidney Injury | 2 | 2026 | 690 | 0.260 |
Why?
|
| DNA Helicases | 2 | 2026 | 235 | 0.260 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 645 | 0.260 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1526 | 0.250 |
Why?
|
| Societies, Medical | 1 | 2011 | 798 | 0.240 |
Why?
|
| Electronics | 2 | 2023 | 45 | 0.230 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 121 | 0.230 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1087 | 0.230 |
Why?
|
| Connectin | 1 | 2025 | 28 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2026 | 5127 | 0.230 |
Why?
|
| Superoxide Dismutase | 1 | 2026 | 179 | 0.230 |
Why?
|
| Human Growth Hormone | 1 | 2025 | 75 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1307 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.220 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.220 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2025 | 165 | 0.210 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.210 |
Why?
|
| Growth Disorders | 1 | 2025 | 184 | 0.210 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 4078 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2025 | 239 | 0.200 |
Why?
|
| Osteosarcoma | 1 | 2026 | 268 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 506 | 0.190 |
Why?
|
| Body Fluids | 1 | 2023 | 46 | 0.190 |
Why?
|
| Metabolome | 1 | 2025 | 328 | 0.190 |
Why?
|
| Dyslipidemias | 1 | 2025 | 250 | 0.190 |
Why?
|
| Genome-Wide Association Study | 3 | 2025 | 1847 | 0.190 |
Why?
|
| Asparaginase | 1 | 2022 | 51 | 0.180 |
Why?
|
| Lipids | 1 | 2026 | 566 | 0.180 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 45 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 46 | 0.180 |
Why?
|
| Metabolomics | 1 | 2025 | 495 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2025 | 6548 | 0.180 |
Why?
|
| Middle Aged | 7 | 2026 | 28963 | 0.180 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 52 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2026 | 453 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 142 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 636 | 0.170 |
Why?
|
| Aftercare | 2 | 2022 | 153 | 0.160 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 142 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 29 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 910 | 0.160 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 36 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 137 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 167 | 0.150 |
Why?
|
| Poverty | 1 | 2023 | 455 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 187 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 125 | 0.150 |
Why?
|
| Hypersensitivity | 1 | 2022 | 231 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 209 | 0.150 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8615 | 0.150 |
Why?
|
| Parents | 2 | 2023 | 1123 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 364 | 0.150 |
Why?
|
| Introns | 1 | 2020 | 288 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 147 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 321 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2022 | 326 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2026 | 3721 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 410 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2025 | 792 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2022 | 385 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1706 | 0.140 |
Why?
|
| Aging, Premature | 1 | 2018 | 32 | 0.140 |
Why?
|
| Remission Induction | 2 | 2016 | 309 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 751 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 253 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 277 | 0.130 |
Why?
|
| Heart Atria | 1 | 2020 | 338 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 500 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 204 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2020 | 532 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 212 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 621 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2658 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 359 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 123 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 313 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 176 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 404 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 542 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 839 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 1476 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1240 | 0.120 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 257 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 578 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 505 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 1709 | 0.110 |
Why?
|
| Quality of Life | 2 | 2024 | 2117 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2018 | 392 | 0.110 |
Why?
|
| Biopsy | 1 | 2018 | 1254 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 894 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 853 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 42 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 44 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 53 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1690 | 0.110 |
Why?
|
| Echocardiography | 1 | 2020 | 1140 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1082 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1420 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1154 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 544 | 0.100 |
Why?
|
| Mutation | 2 | 2020 | 6207 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 321 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 1725 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 899 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 157 | 0.090 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 136 | 0.090 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 351 | 0.090 |
Why?
|
| Age Distribution | 1 | 2013 | 429 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 375 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 680 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1102 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 550 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1032 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1407 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 504 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1522 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 40 | 0.080 |
Why?
|
| Biomarkers | 2 | 2026 | 3429 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2325 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1140 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2010 | 451 | 0.070 |
Why?
|
| Liver Failure | 1 | 2009 | 99 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 482 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 328 | 0.060 |
Why?
|
| Prevalence | 2 | 2026 | 2706 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2026 | 76 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1274 | 0.060 |
Why?
|
| Cranial Irradiation | 1 | 2025 | 74 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1307 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 557 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 29 | 0.050 |
Why?
|
| Selection Bias | 1 | 2024 | 17 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 202 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1863 | 0.050 |
Why?
|
| Pediatrics | 2 | 2025 | 1243 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2026 | 295 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 739 | 0.050 |
Why?
|
| Self Report | 1 | 2026 | 564 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 102 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1484 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 40 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 243 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 179 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 853 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 83 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 380 | 0.040 |
Why?
|
| Logistic Models | 1 | 2026 | 1841 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 2869 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 241 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 403 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2022 | 301 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4550 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 999 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 777 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 43 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 197 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 446 | 0.040 |
Why?
|
| Vaccination | 1 | 2025 | 1041 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 379 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 319 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 801 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1074 | 0.040 |
Why?
|
| Family | 1 | 2021 | 596 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 216 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 444 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2020 | 13022 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 119 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 157 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 711 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1252 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 221 | 0.030 |
Why?
|
| United States | 2 | 2025 | 11867 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 187 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 774 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1304 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7604 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 558 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1602 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 951 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 815 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 22 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 679 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1943 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2995 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1697 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 831 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3858 | 0.020 |
Why?
|
| Aged | 2 | 2023 | 21304 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6289 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 73 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2130 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1083 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 241 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1580 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 281 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3098 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 986 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1019 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 234 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 633 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 463 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2585 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2488 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4699 | 0.010 |
Why?
|